Free Trial

IGM Biosciences (IGMS) Projected to Post Quarterly Earnings on Wednesday

IGM Biosciences logo with Medical background

Key Points

  • IGM Biosciences is set to announce its Q2 2025 earnings on August 13th, with analysts anticipating earnings of ($0.12) per share and revenue of $0.40 million.
  • The company reported a significant earnings surprise in its last quarter, with $1.58 earnings per share against an expectation of ($0.30), alongside revenue of $143.62 million compared to a $3.20 million estimate.
  • IGM Biosciences has a market capitalization of $76.95 million and has recently been downgraded from a "hold" to a "sell" rating by Wall Street Zen, with a consensus price target of $5.50.
  • Looking to export and analyze IGM Biosciences data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

IGM Biosciences (NASDAQ:IGMS - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $0.40 million for the quarter.

IGM Biosciences (NASDAQ:IGMS - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $1.88. IGM Biosciences had a negative return on equity of 93.35% and a negative net margin of 36.81%. The firm had revenue of $143.62 million during the quarter, compared to analysts' expectations of $3.20 million. On average, analysts expect IGM Biosciences to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

IGM Biosciences Price Performance

Shares of NASDAQ:IGMS remained flat at $1.27 during trading on Friday. The stock had a trading volume of 155,302 shares, compared to its average volume of 509,511. IGM Biosciences has a 1 year low of $0.92 and a 1 year high of $22.50. The firm has a market capitalization of $76.35 million, a PE ratio of -1.41 and a beta of 0.60. The business's 50-day moving average price is $1.27 and its 200-day moving average price is $1.29.

Analysts Set New Price Targets

Separately, Wall Street Zen cut IGM Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, June 7th. Two research analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company. According to MarketBeat, IGM Biosciences presently has a consensus rating of "Hold" and an average price target of $5.50.

Read Our Latest Stock Report on IGMS

Institutional Trading of IGM Biosciences

A number of institutional investors have recently made changes to their positions in the company. Invesco Ltd. acquired a new position in IGM Biosciences during the first quarter worth $42,000. Acadian Asset Management LLC acquired a new position in IGM Biosciences during the first quarter worth $97,000. Finally, AQR Capital Management LLC acquired a new position in IGM Biosciences during the first quarter worth $275,000. 42.79% of the stock is owned by institutional investors and hedge funds.

About IGM Biosciences

(Get Free Report)

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.

Read More

Earnings History for IGM Biosciences (NASDAQ:IGMS)

Should You Invest $1,000 in IGM Biosciences Right Now?

Before you consider IGM Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IGM Biosciences wasn't on the list.

While IGM Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

$15 Billion for Cybersecurity: The Government’s Next Big Push
Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines